Literature DB >> 32194151

Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.

T Grellety1, F Peyraud2, N Sevenet3, O Tredan4, N Dohollou5, E Barouk-Simonet6, M Kind7, M Longy3, J-Y Blay4, A Italiano8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32194151     DOI： 10.1016/j.annonc.2020.03.283

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.

Authors:  Benjamin D Leibowitz; Bonnie V Dougherty; Joshua S K Bell; Joshuah Kapilivsky; Jackson Michuda; Andrew J Sedgewick; Wesley A Munson; Tushar A Chandra; Jonathan R Dry; Nike Beaubier; Catherine Igartua; Timothy Taxter
Journal:  BMC Cancer       Date:  2022-05-28       Impact factor: 4.638

2.  PALB2 mutations and prostate cancer risk and survival.

Authors:  Dominika Wokołorczyk; Wojciech Kluźniak; Klaudia Stempa; Bogna Rusak; Tomasz Huzarski; Jacek Gronwald; Katarzyna Gliniewicz; Aniruddh Kashyap; Sylwia Morawska; Tadeusz Dębniak; Anna Jakubowska; Marek Szwiec; Paweł Domagała; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski
Journal:  Br J Cancer       Date:  2021-05-18       Impact factor: 7.640

3.  The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.

Authors:  B Frugtniet; S Morgan; A Murray; S Palmer-Smith; R White; R Jones; L Hanna; C Fuller; E Hudson; A Mullard; A E Quinton
Journal:  BJOG       Date:  2021-11-08       Impact factor: 7.331

4.  Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.

Authors:  Sherko Kuemmel; Hakima Harrach; Rita K Schmutzler; Athina Kostara; Katja Ziegler-Löhr; Mark H Dyson; Ouafaa Chiari; Mattea Reinisch
Journal:  NPJ Breast Cancer       Date:  2020-07-24

Review 5.  Targeting Non-Oncogene Addiction for Cancer Therapy.

Authors:  Hae Ryung Chang; Eunyoung Jung; Soobin Cho; Young-Jun Jeon; Yonghwan Kim
Journal:  Biomolecules       Date:  2021-01-20

6.  Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Xu Liu; Kan Wu; Dan Zheng; Chuanxu Luo; Yu Fan; Xiaorong Zhong; Hong Zheng
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

7.  Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2.

Authors:  Shijie Wu; Lina Qi; Huihui Chen; Kun Zhang; Jiapan He; Xianan Guo; Lu Shen; Yunxiang Zhou; Xi Zhong; Shu Zheng; Jiaojiao Zhou; Yiding Chen
Journal:  NPJ Breast Cancer       Date:  2022-07-19

Review 8.  Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

Authors:  Mariana Paes Dias; Sarah C Moser; Shridar Ganesan; Jos Jonkers
Journal:  Nat Rev Clin Oncol       Date:  2021-07-20       Impact factor: 66.675

Review 9.  Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.

Authors:  Antonella Padella; Andrea Ghelli Luserna Di Rorà; Giovanni Marconi; Martina Ghetti; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Hematol Oncol       Date:  2022-01-22       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.